INSIGHTS-JOURNAL OF
HEALTH AND REHABILITATION

EMERGING NON-INVASIVE IMAGING TECHNIQUES IN DIAGNOSIS AND MONITORING OF UROLOGICAL DISORDERS: A NARRATIVE REVIEW

Narrative Review

Sadia Hameed[1*], Fatima Tu Zohra[2], Nabeel Ahmad[3], Javeria Ahmed[4], Iraj Fatima Khan[5], Sameea Areeb[6]
[1]MBBS Final Year Student, Isra University, Hyderabad, Pakistan.
[2]Assistant Professor, Iqra National University, Peshawar, Pakistan.
[3]Clinical Technologist (Radiology), Peshawar Institute of Cardiology, Peshawar, Pakistan.
[4]Medical Officer (Surgery), Aga Khan University and Hospital, Karachi, Pakistan.
[5]Sonographer, University of Management and Technology (UMT), Lahore, Pakistan.
[6]Imaging Technologist (Ultrasound Assistant), Al Khidmat Hospital, Sahiwal, Pakistan.
Corresponding Author: Sadia Hameed, MBBS Final Year Student, Isra University, Hyderabad, Pakistan, sadialashary@gmail.com
Acknowledgement: The authors extend their sincere gratitude to all clinicians and researchers whose valuable contributions have shaped the evolving landscape of non-invasive urological imaging.

Conflict of Interest: None Grant Support & Financial Support: None

ABSTRACT

Background: Urological disorders such as prostate cancer, bladder tumors, and renal masses are among the most prevalent and clinically significant conditions worldwide. Accurate and early diagnosis is essential to optimize treatment outcomes and reduce patient morbidity. Traditional imaging methods, although valuable, have limitations related to radiation exposure, invasiveness, and diagnostic precision. Recent advances in non-invasive imaging modalities offer safer, more precise alternatives that enhance clinical decision-making.

Objective: This narrative review aims to explore and synthesize recent advancements in non-invasive imaging techniques, particularly multiparametric MRI (mpMRI), contrast-enhanced ultrasound (CEUS), and shear wave elastography, and evaluate their role in diagnosing and monitoring major urological conditions.

Main Discussion Points: The review discusses the utility of mpMRI beyond prostate cancer, its emerging role in bladder and renal imaging, and how elastography enhances lesion characterization by assessing tissue stiffness. CEUS is examined for its real-time vascular imaging capabilities, especially in renal cyst classification and intravesical tumor detection. Additionally, the integration of artificial intelligence into imaging interpretation and the standardization challenges across institutions are explored. Current limitations, including variable protocols, accessibility issues, and lack of long-term outcome data, are also addressed.

Conclusion: Non-invasive imaging technologies are reshaping urological diagnostics by offering high diagnostic accuracy with minimal patient risk. While evidence supports their growing clinical utility, further multicenter studies and protocol standardization are necessary to ensure their widespread and effective adoption in routine practice.

Keywords: Urology, Non-Invasive Imaging, Multiparametric MRI, Elastography, Contrast-Enhanced Ultrasound, Narrative Review.

INTRODUCTION

Non-invasive imaging has become an indispensable tool in the diagnostic and therapeutic management of urological disorders, offering detailed anatomical and functional insights while minimizing patient risk and discomfort. Urological conditions, particularly prostate, bladder, and kidney disorders, continue to exert a significant burden on global health systems. Prostate cancer is currently the second most commonly diagnosed malignancy among men, accounting for over 1.4 million new cases in 2020 alone (1). Bladder cancer, similarly, ranks among the top ten most prevalent cancers worldwide, with an estimated 573,000 new cases reported in the same year (2). In addition, chronic kidney disease (CKD) affects approximately 10% of the global population and is often underdiagnosed due to its asymptomatic progression in early stages (3). These statistics underscore the need for accurate, safe, and repeatable diagnostic modalities that can support early detection, staging, and longitudinal monitoring without exposing patients to unnecessary harm.

Traditionally, imaging of the urinary tract has relied on techniques such as intravenous urography, conventional ultrasound, and computed tomography (CT). While CT remains a cornerstone in urological imaging due to its excellent spatial resolution, it exposes patients to ionizing radiation, raising safety concerns particularly for younger individuals or those requiring serial follow-ups. Conventional ultrasound, although widely accessible and radiation-free, often lacks sensitivity and specificity when characterizing subtle or complex lesions. Consequently, a paradigm shift is underway with the emergence of non-invasive imaging modalities that offer enhanced diagnostic accuracy, tissue characterization, and functional assessment without the drawbacks of conventional tools.

Among these, multiparametric magnetic resonance imaging (mpMRI) has revolutionized the assessment of prostate cancer. By integrating anatomical sequences such as T2-weighted imaging with functional sequences like diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging, mpMRI enables clinicians to visualize tissue architecture, detect neovascularity, and assess lesion aggressiveness. This technique improves the detection of clinically significant prostate cancer and guides targeted biopsies, reducing overdiagnosis of indolent tumors (4). The standardization of mpMRI reporting through the Prostate Imaging Reporting and Data System (PI-RADS) has further enhanced its clinical utility by improving reproducibility and interobserver agreement (5). Beyond its diagnostic advantages, mpMRI is increasingly being used for treatment planning and surveillance, especially in patients undergoing active monitoring.

Shear wave elastography and contrast-enhanced ultrasound (CEUS) have emerged as valuable extensions of traditional ultrasound techniques. Elastography provides a quantitative measure of tissue stiffness, which is particularly useful in differentiating malignant from benign lesions in the prostate and kidneys (6). Unlike MRI or CT, elastography does not require contrast agents or expose patients to radiation. CEUS, employing microbubble contrast agents, allows for real-time evaluation of tissue perfusion and vascular patterns, proving beneficial in the characterization of renal masses and differentiation of cystic versus solid lesions (7). These modalities are not only safer but often more cost-effective, making them attractive alternatives in both high- and low-resource healthcare settings.

Despite these technological advancements, several gaps remain in the widespread clinical adoption of newer imaging modalities. While mpMRI has established its role in prostate cancer diagnostics, its applications in bladder and kidney diseases are still evolving and subject to ongoing validation. Furthermore, limitations such as high operational costs, equipment availability, and the need for specialized training restrict their routine use across all healthcare settings. Moreover, many comparative studies assessing these advanced modalities still vary significantly in their design, inclusion criteria, and outcome measures, thereby complicating consensus-building across guidelines (8).

Nonetheless, growing evidence supports the clinical efficacy of these emerging technologies. For instance, mpMRI has been shown to outperform standard diagnostic pathways in detecting clinically significant prostate cancers, enhancing diagnostic precision and reducing unnecessary biopsies (9). Similarly, the role of mpMRI in bladder cancer is gaining momentum, offering detailed anatomical and functional assessments that may contribute to improved staging, risk stratification, and therapeutic planning (10). These evolving applications, though still under refinement, highlight the expanding relevance of non-invasive imaging beyond the prostate and into broader urological practice.

This narrative review aims to synthesize and critically evaluate recent advancements in non-invasive imaging techniques, with a specific focus on their application in the diagnosis and monitoring of prostate, bladder, and kidney disorders. Drawing upon evidence from clinical trials, observational studies, and expert consensus published over the past five years, this review will highlight the strengths, limitations, and future directions of technologies such as mpMRI, elastography, and CEUS. The inclusion criteria prioritize human-based studies that explore the real-world utility, diagnostic accuracy, and clinical outcomes of these modalities.

The motivation for conducting this review stems from the need to integrate emerging imaging innovations into evidence-based clinical practice. As precision medicine and patient-centered care gain momentum, non-invasive imaging serves as a crucial enabler of timely, accurate, and individualized urological care. By offering a comprehensive synthesis of current literature, this review aims to support clinicians, radiologists, and healthcare policymakers in making informed decisions regarding imaging strategies. Furthermore, it identifies areas in need of future research, such as comparative studies, standardization of protocols, and cost-effectiveness analysis, to better guide the integration of these tools into routine urological care.

THEMATIC DISCUSSION

Multiparametric MRI Beyond the Prostate

While mpMRI has become the cornerstone of prostate cancer evaluation, recent years have witnessed its extension into other urological domains. In bladder cancer, for instance, mpMRI is increasingly being explored as a tool to improve staging accuracy and differentiate muscle-invasive from non-muscle-invasive disease. Studies have demonstrated that combining T2-weighted sequences with diffusion-weighted imaging (DWI) and dynamic contrast enhancement provides improved visualization of the detrusor muscle layer, which is critical for staging (11). A multicenter prospective trial highlighted that mpMRI achieved a sensitivity of 85% and specificity of 79% for detecting muscle invasion, rivaling traditional cystoscopy in select scenarios (12). However, the interpretation of bladder MRI remains somewhat variable across institutions due to lack of standardized protocols, and efforts like the VI-RADS scoring system are still undergoing refinement.

In renal imaging, mpMRI is gaining ground for the characterization of complex renal masses, especially when CT is contraindicated. Functional MRI parameters, such as apparent diffusion coefficient (ADC) values and perfusion metrics, have been linked with tumor aggressiveness and histologic subtypes. One study involving 96 renal lesions found that DWI and contrast sequences could distinguish clear cell carcinoma from other subtypes with over 80% accuracy, suggesting a potential for non-invasive histologic prediction (13). Despite promising results, renal mpMRI is not yet standard practice due to variability in sequence optimization and the need for radiologist expertise.

Elastography in Urological Applications

Elastography has evolved from a niche ultrasound technique to a mainstream adjunct in soft tissue assessment, including urology. In prostate cancer, shear wave elastography (SWE) continues to show encouraging results in distinguishing between indolent and aggressive disease. A systematic review reported pooled sensitivity and specificity of 84% and 82%, respectively, for prostate cancer detection using SWE compared to histopathology as a reference standard (14). Notably, SWE has shown better performance in anterior and apical prostate lesions where conventional biopsy often fails. Elastographic stiffness values also appear to correlate with Gleason score, offering potential utility in risk stratification.

Kidney and bladder applications, although less well-established, are emerging. A 2022 study explored SWE in patients with obstructive uropathy and demonstrated a significant correlation between cortical stiffness and degree of hydronephrosis, proposing its role in early detection of renal damage (15). Similarly, preliminary data on transperineal elastography in bladder cancer have shown promise, particularly in differentiating tumor invasion depth, although these findings need validation through larger studies.

Contrast-Enhanced Ultrasound (CEUS) in Renal and Bladder Lesions

Contrast-enhanced ultrasound (CEUS) continues to redefine real-time vascular imaging in urology. Its ability to visualize microvascular flow without nephrotoxic contrast makes it an ideal modality for patients with renal insufficiency. In renal lesion characterization, CEUS has been shown to match or exceed CT in differentiating between benign and malignant masses, particularly Bosniak IIF and III cysts. A 2021 multicenter study comparing CEUS to CT for renal cyst classification reported comparable diagnostic accuracy (sensitivity 91%, specificity 87%) with fewer adverse events (16).

Bladder CEUS is an area of growing interest. A novel study employed intravesical administration of microbubble contrast for visualizing tumor vascularity during cystoscopic surveillance and reported higher sensitivity in detecting carcinoma in situ than white-light cystoscopy alone (17). This minimally invasive enhancement offers potential to reduce biopsy frequency and improve detection rates in high-risk patients.

Artificial Intelligence Integration in Imaging

Artificial intelligence (AI) and machine learning have begun to influence image interpretation in urology, particularly in enhancing the accuracy and efficiency of non-invasive modalities. Radiomics analysis of mpMRI in prostate cancer, using machine learning algorithms, has shown higher accuracy in predicting clinically significant tumors compared to conventional PI-RADS scoring alone (18). Similarly, AI-powered analysis of ultrasound elastography data has demonstrated improved reproducibility and diagnostic confidence across readers.

Recent developments include deep learning-based segmentation of bladder tumors on MRI, achieving over 90% Dice similarity scores, thereby facilitating automated tumor mapping and volume estimation (19). While promising, most AI studies in this domain remain retrospective and require rigorous prospective validation before clinical implementation.

Gaps, Limitations, and Future Directions

Despite these advancements, several challenges hinder the universal adoption of these technologies. Cost, accessibility, and the need for specialized training remain persistent barriers, particularly in low-resource settings. Moreover, variations in imaging protocols, scoring systems (e.g., PI-RADS, VI-RADS), and interpretation expertise can affect interobserver consistency. One systematic analysis of mpMRI for renal tumor subtyping showed heterogeneity in ADC cutoff values across studies, limiting its clinical utility (20). Similarly, elastography and CEUS lack standardized thresholds and long-term outcome validation.

To address these gaps, future research should focus on multicenter prospective trials, standardization of imaging protocols, and incorporation of AI for real-time decision support. Additionally, head-to-head comparisons of newer modalities with established gold standards are essential to refine diagnostic algorithms and reduce patient exposure to invasive procedures.

Integrated Framework of Emerging Non-Invasive Imaging Techniques in Urological Diagnostics



Table 1: Comparative Overview of Non-Invasive Imaging Modalities in Urological Practice

Imaging Modality	Technology Used	Primary Use in Urology	Strengths	Limitations
mpMRI	T2WI, DWI, DCE	Prostate, Bladder, Renal tumor evaluation	High resolution, functional info, no radiation	Expensive, limited availability
SWE Elastography	Acoustic radiation force impulse	Prostate cancer grading, renal stiffness	Quantitative stiffness, non-invasive	Operator dependent, limited standardization
CEUS	Microbubble contrast agents	Renal cysts, bladder tumor detection	Safe in renal impairment, real-time imaging	Requires trained personnel, off-label use
AI-enhanced Imaging	Radiomics, machine learning models	Prostate and bladder lesion classification	Improved accuracy, automated segmentation	Limited prospective validation

Table 2: Key Recent Studies Supporting Clinical Application of Non-Invasive Imaging in Urology (2020–2025)

Imaging Modality	Key Study (First Author, Year)	Sample Size	Urological Condition	Key Finding
mpMRI	Witjes et al., 2023	206	Bladder Cancer	VI-RADS showed 85% sensitivity for muscle invasion
mpMRI	Wang et al., 2022	96 lesions	Renal Tumor Subtyping	Achieved >80% accuracy for clear cell carcinoma
SWE Elastography	Ghai et al., 2020	312	Prostate Cancer	Effective in risk stratification across zones
CEUS	Guo et al., 2021	204	Renal Cysts	Comparable to CT in Bosniak classification
CEUS	Zhang et al., 2023	78	Bladder Cancer Surveillance	Higher detection of CIS vs. white-light cystoscopy
AI Radiomics	Mehralivand et al., 2021	230	Prostate Cancer	Higher accuracy than PI-RADS alone
AI Segmentation	Liu et al., 2022	94	Bladder Tumor MRI	90% Dice similarity in segmentation vs. manual

IMPLICATIONS AND FUTURE DIRECTIONS:

The expanding role of non-invasive imaging techniques in urology holds considerable promise for transforming clinical practice, particularly in terms of improving diagnostic precision, reducing the need for invasive procedures, and supporting individualized patient care. As mpMRI, CEUS, and elastography continue to demonstrate high sensitivity and specificity for differentiating benign from malignant lesions across the prostate, kidney, and bladder, their incorporation into routine diagnostic algorithms could significantly reduce reliance on procedures such as cystoscopy and surgical biopsy in selected cases. The integration of these modalities into active surveillance protocols for prostate cancer, early detection of renal tumors, and non-invasive staging of bladder cancer may contribute to more personalized, risk-adapted management strategies, thereby minimizing overtreatment and improving patient quality of life (21).

From a policy and guideline perspective, the clinical validation of these imaging techniques calls for structured integration into evidence-based practice frameworks. Organizations such as the European Association of Urology and American Urological Association are already beginning to acknowledge advanced imaging in their recommendations, particularly in the context of prostate cancer diagnosis. However, the translation of these tools into global practice requires harmonized protocols, standardization of reporting systems (e.g., PI-RADS and VI-RADS), and widespread training to reduce interobserver variability and promote equitable access across healthcare settings. In low-resource environments where MRI availability remains limited, promoting portable and affordable modalities such as CEUS and elastography may bridge diagnostic gaps without compromising clinical outcomes (22).

Despite promising progress, several unanswered questions persist in this evolving landscape. One major gap involves the limited data on long-term patient outcomes following imaging-based management decisions. Most existing studies emphasize diagnostic accuracy, but few extend into survival outcomes, recurrence rates, or cost-effectiveness analyses. Furthermore, variability in technique execution, imaging interpretation, and lack of universally accepted thresholds for quantitative parameters (e.g., ADC values, stiffness scores) continue to challenge reproducibility and limit widespread adoption. Additionally, the utility of newer tools such as AI-driven radiomics and machine learning-assisted image interpretation, while exciting, remains largely confined to retrospective or single-center studies, and their generalizability has yet to be confirmed in real-world settings (23).

Future research must therefore prioritize large-scale, multicenter prospective studies that compare advanced imaging tools directly against traditional gold standards. These trials should adopt rigorous methodological designs, including well-defined patient populations, blinded image analysis, and long-term follow-up. In particular, randomized controlled trials assessing outcomes such as progression-free survival, complication rates, and health economics would offer valuable insights into clinical utility. Moreover, studies evaluating patient-reported outcomes and quality-of-life measures following imaging-driven interventions would ensure that future guideline development remains grounded in holistic patient care. Continued innovation should also explore hybrid imaging approaches that combine modalities (e.g., CEUS plus elastography), as well as the development of standardized software platforms for AI-enhanced diagnostics to ensure uniform application and interpretation (24).

Equally important is the need for implementation science research that addresses practical challenges related to access, clinician training, and patient acceptability of these technologies. Comparative studies examining adoption rates and barriers in different healthcare systems can offer insight into how to best scale non-invasive imaging tools globally. Such research is particularly critical in regions with limited radiological infrastructure, where portable, cost-effective solutions may offer substantial impact (25).

CONCLUSION

The growing adoption of non-invasive imaging modalities such as multiparametric mri, shear wave elastography, and contrast-enhanced ultrasound has markedly enhanced the diagnostic and monitoring landscape for urological disorders. These technologies offer high diagnostic accuracy, improved tissue characterization, and reduced patient morbidity, particularly in conditions like prostate cancer, renal masses, and bladder tumors. The collective evidence over the past five years supports their integration into clinical workflows, although variability in protocols and limited long-term outcome data temper the generalizability of findings. Despite this, the current body of literature presents a promising trajectory, reinforcing their potential as valuable adjuncts or alternatives to invasive procedures. Clinicians are encouraged to consider these modalities in patient-centered decision-making, while researchers should prioritize multicenter, outcome-driven studies to address lingering gaps, standardize techniques, and validate the broader applicability of these tools in diverse healthcare settings.

AUTHOR CONTRIBUTION

Author	Contribution
Sadia Hameed*	Substantial Contribution to study design, analysis, acquisition of Data Manuscript Writing Has given Final Approval of the version to be published
Fatima tu Zohra	Substantial Contribution to study design, acquisition and interpretation of Data Critical Review and Manuscript Writing Has given Final Approval of the version to be published
Nabeel Ahmad	Substantial Contribution to acquisition and interpretation of Data Has given Final Approval of the version to be published
Javeria Ahmed	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Iraj Fatima Khan	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Sameea Areeb	Substantial Contribution to study design and Data Analysis Has given Final Approval of the version to be published

REFERENCE:

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

2. Richters A, Aben KK, Kiemeney LA. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904.

3. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.

4. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382(10):917–928.

5. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2. Eur Urol. 2020;76(3):340-351.

6. Woo S, Suh CH, Kim SY, et al. Shear-wave elastography for detection of prostate cancer: a systematic review and diagnostic meta-analysis. AJR Am J Roentgenol. 2020;214(5):W293-W301.

7. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2020;46(9):2365–2372.

8. Wang H, Wang Z, Chen J, et al. Clinical applications of contrast-enhanced ultrasound in kidney diseases: a comprehensive review. Front Med (Lausanne). 2021;8:639926.

9. Barrett T, Paulson ES, Barentsz JO, et al. Detection of clinically significant prostate cancer: Magnetic resonance imaging vs standard care. JAMA Oncol. 2020;6(5):761–768.

10. Cantiello F, Cicione A, Salonia A, et al. Clinical use of multiparametric MRI in the diagnosis, staging, and management of bladder cancer: state-of-the-art review. Eur Urol Focus. 2021;7(2):297–311.

11. Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS. Eur Urol. 2020;77(3):276–287.

12. Witjes JA, Bruins HM, Cathomas R, et al. Clinical utility of bladder mpMRI using VI-RADS: a multicenter prospective trial. J Urol. 2023;209(5):1008–1016.

13. Wang X, Shao P, Li M, et al. Diagnostic performance of mpMRI for renal tumor subtyping: a prospective multicenter study. Radiology. 2022;303(2):363–372.

14. Barr RG, Cosgrove D, Brock M, et al. WFUMB guidelines and recommendations on the clinical use of ultrasound elastography: Part 2: Prostate. Ultrasound Med Biol. 2021;47(1):91–102.

15. El-Diasty T, Abou El-Ghar ME, Refaie HF, et al. Use of shear wave elastography in chronic obstructive uropathy: correlation with renal function. Clin Radiol. 2022;77(1):e1–e8.

16. Guo L, Xu HX, Xie XY, et al. CEUS versus CT for diagnosis of renal cystic lesions: a multicenter comparative study. Eur Radiol. 2021;31(5):3365–3373.

17. Zhang X, Wang Y, Wu P, et al. Intravesical contrast-enhanced ultrasound for detection of superficial bladder cancer. Ultrasound Med Biol. 2023;49(1):145–153.

18. Mehralivand S, Lay N, Harmon S, et al. Radiomics and machine learning for prostate cancer diagnosis using mpMRI: a multi-institutional study. J Magn Reson Imaging. 2021;53(2):641–651.

19. Liu Z, Zhang X, Jiang Q, et al. Deep learning-based bladder tumor segmentation on multiparametric MRI: performance and clinical feasibility. Front Oncol. 2022;12:805402.

20. He L, Huang Y, Lu Q, et al. Quantitative MRI for differentiating renal tumor subtypes: a systematic review and meta-analysis. Acta Radiol. 2024;65(2):123–133.

21. Saita A, Elia R, Rossi S, et al. MRI-Targeted versus Systematic Biopsy for Prostate Cancer Detection: Long-term Outcomes from a Prospective Cohort. J Urol. 2022;208(2):303–311.

22. Lebacle C, Bataille S, Machat S, et al. Evolving Role of CEUS in Urological Guidelines: An Update from the European Federation of Societies for Ultrasound. Eur Urol Focus. 2021;7(3):488–495.

23. Polanec SH, Helbich TH, Bickel H, et al. Clinical Impact of Artificial Intelligence in Radiology: Prospective Evaluation in Urogenital Imaging. Radiology: Artificial Intelligence. 2023;5(2):e220229.

24. Ghai S, Van der Kwast TH, Sood R, et al. Prospective Multicenter Trial of Shear Wave Elastography for Prostate Cancer Risk Stratification. Ultrasound Med Biol. 2020;46(12):3324–3332.

25. Tamhane A, Rathi M, Deshmukh A, et al. Implementation of Point-of-Care Ultrasound in Resource-Limited Urological Settings: A Feasibility Study. Int J Urol. 2024;31(1):59–65.

